Top Core and Group Health Stories
Eli Lilly sues companies that allegedly sold unapproved versions of new GLP-1
By Alan Goforth"Retatrutide is being rigorously studied as part of a comprehensive clinical trial development program," David A. Hyman, M.D., Lilly's chief medical officer, said in a news release.








